CorMedix Inc. (CRMD) News

CorMedix Inc. (CRMD): $4.26

-0.05 (-1.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter CRMD News Items

CRMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CRMD News From Around the Web

Below are the latest news stories about CORMEDIX INC that investors may wish to consider to help them evaluate CRMD as an investment opportunity.

Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections

BERKELEY HEIGHTS, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the abstract publication and poster presentation at the American Society of Health-System Pharmacists (ASHP) conference in Las Vegas, Nevada, December 4 – 8. The abstract being presented highlights research that was conducted b

Yahoo | December 6, 2022

How did CorMedix Inc. (CRMD) fare last session?

CorMedix Inc. (NASDAQ:CRMD) closed Wednesday at $3.99 per share, up from $3.90 a day earlier. While CorMedix Inc. has overperformed by 2.31%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRMD fell by -22.07%, with highs and lows ranging from $8.02 to $2.64, whereas the simple […]

US Post News | November 24, 2022

CorMedix Third Quarter 2022 Earnings: US$0.17 loss per share (vs US$0.23 loss in 3Q 2021)

CorMedix ( NASDAQ:CRMD ) Third Quarter 2022 Results Key Financial Results Net loss: US$6.85m (loss narrowed by 20% from...

Yahoo | November 12, 2022

Analysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), TG Therapeutics (TGTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cormedix (CRMD – Research Report) and TG Therapeutics (TGTX – Research Report) with bullish sentiments. Cormedix (CRMD) Needham analyst Serge Belanger maintained a Buy rating on Cormedix today and set a price target of $13.00. The company's shares closed last Thursday at $3.09, close to its 52-week low of $2.65. According to TipRanks.

Howard Kim on TipRanks | November 10, 2022

JMP Securities Remains a Buy on Cormedix (CRMD)

E ratio of -3.52.

Catie Powers on TipRanks | November 10, 2022

CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

GlobeNewswire | November 10, 2022

CorMedix (CRMD) Q3 2022 Earnings Call Transcript

CorMedix Inc. (NASDAQ:NASDAQ:CRMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 am ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice…

Seeking Alpha | November 10, 2022

CorMedix GAAP EPS of -$0.17 beats by $0.06, revenue of $6.82M (NASDAQ:CRMD)

CorMedix press release (CRMD): Q3 GAAP EPS of -$0.17 beats by $0.06.Revenue of $6.82M (-82.1% Y/Y).Total cash on hand and short-term investments as of September 30, 2022 was…

Seeking Alpha | November 10, 2022

CorMedix Inc Common Stock (CRMD) Q3 2022 Earnings Call Transcript

CRMD earnings call for the period ending September 30, 2022.

The Motley Fool | November 10, 2022

CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath

BERKELEY HEIGHTS, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that the Center for Medicare & Medicaid Services (CMS) has published in the Federal Register a correction to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals New Technology Add on Payment (NTAP) reimb

Yahoo | November 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5509 seconds.